<DOC>
	<DOC>NCT02991768</DOC>
	<brief_summary>The purpose of this study is to learn if using a Entocort (budesonide) to treat diarrhea will be effective and safe for kidney transplant patients, allowing them to continue with MPA medication.</brief_summary>
	<brief_title>Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Kidney transplant recipients &gt; 3 months posttransplant, No history of chronic diarrhea pretransplant, &gt;3 watery/soft stools after transplant on at least 4 days in the week without antidiarrheal for at least 2 weeks or using antidiarrheals for at least 4 days in the week &gt; 2 weeks Subjects on at least 180mg twice a day of mycophenolatesodium or 250 mg twice a day of cellcept Diagnosis of any known colonic diseases (i.e. Crohn's disease, ulcerative colitis, ischemic colitis, Celiac disease), partial colonic resection, small bowel resection, history of cholecystectomy, Irritable Bowel Syndrome, fecal Incontinence, Bacterial overgrowth, infectious diarrhea (c difficle, cryptospora, giardia, isospora, Human Immunodeficiency Virus), Cytomegalovirus colitis Subjects with recent acute rejection treated with high dose steroids Subjects taking Boswellia serrata extract, overthecounter herbs, cholestyramine, nonsteroidal salicylates (other than daily ASA) Subjects with active malignancy, liver cirrhosis, active peptic ulcer disease, known intolerance or resistance to budesonide, pregnancy, breastfeeding, mental retardation Unable to provide informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>